

Alexa Fluor® 647 anti-human CD273 (B7-DC, PD-L2)

Catalog # / Size: 2327570 / 100 tests
2327565 / 25 tests

Clone: MIH18

Isotype: Mouse IgG1, κ


Immunogen: Human B7-DC transfected cells

Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 647 under optimal conditions. The solution is free of unconjugated Alexa Fluor® 647.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

Concentration: Lot-specific



Human monocyte-derived dendritic cells were stained with CD273 (Clone MIH18) Alexa Fluor® 647 (filled histogram) or mouse IgG1, κ isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor® 647 has a maximum emission of 668 nm when it is excited at 633 nm / 635 nm.

Application Notes: Additional reported applications (for the relevant formats) include: blocking^{4,5}, and immunohistochemistry in frozen sections² and paraffin-embedded formalin-fixed sections⁶.

Application References: 1. Carreno BM, *et al.* 2002. *Annu. Rev. Immunol.* 20:29.
2. Ohigashi Y, *et al.* 2005. *Clin. Cancer. Res.* 8:2947.

Description: CD273, known as B7-DC, is also called programmed death ligand 2 (PDL2). This ligand is a 25 kD type I transmembrane protein and a member of B7 family within the immunoglobulin receptor superfamily and is expressed on a subset of dendritic cells, liver and a small subset of macrophages as well as a few transformed cell lines. CD273 has been reported to be stimulatory on dendritic cells when cross-linked and to inhibit T cell activation upon engaging the PD-1 receptor. CD273 has also been reported to bind to an alternative receptor and to mediate T cell activation through such non-PD1 mediated interactions. Clone MIH18 is reported to block PDL2.

Antigen References: 1. Carreno BM, *et al.* 2002. *Annu. Rev. Immunol.* 20:29.
2. Ohigashi Y, *et al.* 2005. *Clin. Cancer. Res.* 8:2947.